Johnson & Johnson (NYSE:JNJ) took another step towards its $2.4 billion acquisition of Crucell N.V. (NSDQ:CRXL).
The companies announced that the minimum acceptance condition of Johnson & Johnson’s offer to acquire Crucell was satisfied.
When the offer expired on Feb. 16, the shares tendered in the deal represent 95 percent of the issued and outstanding share capital of Crucell on a fully diluted basis.